Advertisement

Comment gérer au mieux la toxicité des traitements antiangiogéniques?

  • Bernard Escudier
  • Caroline Robert
Chapter
  • 335 Downloads
Part of the Oncologie pratique book series (ONCOLPRAT)

Abstrait

Le traitement du cancer du rein métastatique (CRM) a été transformé par ľavènement des antiangiogéniques: sunitinib (Sutent®) et sorafénib (Nexavar®), en attendant que le temsirolimus (Torisel®) et le bévacizumab (Avastin®) obtiennent à leur tour leur autorisation de mise sur le marché (AMM). Ce chapitre traite uniquement des deux premiers antiangiogéniques, qui ont obtenu ľAMM en 2006 dans le traitement du CRM.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Houk BE, Bello CL, Michaelson MD et al. (2007) Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): A population pharmacokinetic/pharmacodynamic (PKPD) approach. J Clin Oncol, ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement): 5027Google Scholar
  2. 2.
    Amato RJ, Harris P, Dalton M et al. (2007) A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement): 5026Google Scholar
  3. 3.
    Bukowski R, Cella D, Gondek K et al. (2007) Effects of sorafenib on symptoms and quality-of-life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol 30: 220–7PubMedCrossRefGoogle Scholar
  4. 4.
    Robert C, Soria JC, Spatz A et al. (2005) Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6: 491–500PubMedCrossRefGoogle Scholar
  5. 5.
    Motzer RJ, Hutson TE, Tomczak P et al. (2007) Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma. N Engl J Med 356: 115–124PubMedCrossRefGoogle Scholar
  6. 6.
    Escudier B, Eisen T, Stadler WM et al. (2007) Treatment Approaches in Renal cancer Global Evaluation Trial (TARGETs): A Randomized, Double-Blind Placebo-Controlled Phase III Trial of Sorafenib, an Oral Multi-Kinase Inhibitor in Advanced Renal Cell Carcinoma. N Engl J Med 356: 125–34PubMedCrossRefGoogle Scholar
  7. 7.
    Robert C, Faivre S, Raymond E et al. (2005) Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors? Ann Intern Med 143: 313–4PubMedGoogle Scholar
  8. 8.
    Calabrese C, Fabbri A, Areni A et al. (2007) Mesalazine with or without cholestyramine in the treatment of microscopic colitis: randomized controlled trial. J Gastroenterol Hepatol 22: 809–14PubMedCrossRefGoogle Scholar
  9. 9.
    Sane DC, Anton L, Brosnihan KB (2004) Angiogenic growth factors and hypertension. Angiogenesis 7: 193–201PubMedCrossRefGoogle Scholar
  10. 10.
    Izzedine H, Rixe O, Billemont B et al. (2007) Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis 50: 203–18PubMedCrossRefGoogle Scholar
  11. 11.
    Force T, Krause DS, Van Etten RA. (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7: 332–44PubMedCrossRefGoogle Scholar
  12. 12.
    Faivre S, Delbaldo C, Vera K et al. (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24: 25–35PubMedCrossRefGoogle Scholar
  13. 13.
    Rini BI, Tamaskar I, Shaheen P et al. (2007) Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99: 81–3PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag France, Paris 2008

Authors and Affiliations

  • Bernard Escudier
    • 1
  • Caroline Robert
    • 1
  1. 1.Institut Gustave Roussy VillejuifVillejuifFrance

Personalised recommendations